

ALKERMES INC  
Form 8-K  
November 02, 2007

**Table of Contents**

**SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K  
CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934  
Date of report (Date of earliest event reported): October 31, 2007  
ALKERMES, INC.  
(Exact Name of Registrant as Specified in its Charter)**

<b>PENNSYLVANIA</b> (State or Other Jurisdiction of Incorporation)	<b>1-14131</b> (Commission File Number)	<b>23-2472830</b> (I.R.S. Employer Identification No.)
--	---	--

<b>88 Sidney Street</b> <b>Cambridge, Massachusetts</b> (Address of principal executive offices)	<b>02139</b> (Zip Code)
--	----------------------------

Registrant's telephone number, including area code: **(617) 494-0171**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**TABLE OF CONTENTS**

Item 8.01 Other Events

Item 9.01 Financial Statements and Exhibits

SIGNATURE

EXHIBIT INDEX

EX-99.1 Press release issued by Alkermes, Inc., dated October 31, 2007

---

**Table of Contents**

**Item 8.01 Other Events**

On October 31, 2007, Alkermes, Inc. issued a press release announcing positive results from a 30-week comparator study of once-weekly exenatide long-acting release (LAR) injection and BYETTA<sup>®</sup> (exenatide) injection taken twice daily in patients with type 2 diabetes.

**Item 9.01 Financial Statements and Exhibits**

**(d) Exhibits**

**Exhibit No. Description**

- |      |  |
|------|--|
| 99.1 | Press release issued by Alkermes, Inc. dated October 31, 2007 announcing positive results from a 30-week comparator study of once-weekly exenatide long-acting release (LAR) injection and BYETTA <sup>®</sup> (exenatide) injection taken twice daily in patients with type 2 diabetes. |
|------|--|
-

**Table of Contents**

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ALKERMES, INC.**

Date: November 2, 2007

By: /s/ James M. Frates  
James M. Frates  
Senior Vice President, Chief Financial  
Officer and Treasurer (Principal  
Financial and Accounting Officer)

---

**Table of Contents**

**EXHIBIT INDEX**

- 99.1 Press release issued by Alkermes, Inc. dated October 31, 2007 announcing positive results from a 30-week comparator study of once-weekly exenatide long-acting release (LAR) injection and BYETTA<sup>®</sup> (exenatide) injection taken twice daily in patients with type 2 diabetes.